Core Viewpoint - The company has announced an increase in trading volume of its H-shares on January 9, 2026, and confirmed no knowledge of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares by its controlling shareholder, Luye Pharma Group [1][2] Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which can be exchanged for 100.5 million H-shares held by Luye Pharma Group [1][2] - To comply with the agreement related to the exchangeable preferred shares, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer on the market [1] Group 2: Product Development and Approval - The company announced that its self-developed drug, BA6101 (60mg), has been approved for marketing by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2] - BA6101 is a biosimilar to the reference drug Prolia, widely used for the treatment of osteoporosis, and shares the same indications as the reference drug [2][3] - The development of BA6101 adhered to international guidelines, confirming its overall similarity to the reference drug in terms of quality, safety, and efficacy [3] Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and has established strategic partnerships for its commercialization in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [3] - The company aims to accelerate its international strategy by providing high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [3]
博安生物：成交量异常变动及地舒单抗在玻利维亚获批上市